Eli Lilly's Donanemab Approval Heats Up Alzheimer's Disease Treatment Market | DelveInsight [Yahoo! Finance]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Yahoo! Finance
This approval will intensify the competition between Eli Lilly's Donanemab and Biogen and Eisai's ADUHELM (aducanumab), and LEQEMBI (lecanemab). LAS VEGAS July 8, 2024 /PRNewswire/ -- Alzheimer's disease, the most common type of dementia, is a progressive neurodegenerative disorder with a multifactorial pathogenesis. It is characterized by a gradual decline in cognitive and functional abilities, with individuals eventually losing the ability to undertake everyday tasks and function independently. As per DelveInsight analysis, in 2023, the total diagnosed prevalent cases of Alzheimer's disease in the 7MM were 15.4 million . These cases are projected to increase further during the forecast period (2024–2034). In 2023, the United States had the highest proportion of diagnosed prevalent cases of Alzheimer's disease among the 7MM, comprising approximately of the total cases. Conversely, the United Kingdom had the lowest share, representing nearly of the total diagnosed prevalent case
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- What end of Eli Lilly's weight-loss drug shortage means for the competition [Yahoo! Finance Canada]Yahoo! Finance Canada
- Eli Lilly's Mounjaro, Zepbound removed from FDA's shortage list [Yahoo! Finance Canada]Yahoo! Finance Canada
- What end of Eli Lilly's weight-loss drug shortage means for the competition [Yahoo! Finance]Yahoo! Finance
- England's NHS Proposes Phased Rollout of Eli Lilly's Mounjaro, Considers Digital Services to Boost Access [Yahoo! Finance]Yahoo! Finance
- NHS proposes phased launch for Eli Lilly's Mounjaro [Yahoo! Finance]Yahoo! Finance
LLY
Earnings
- 8/8/24 - Beat
LLY
Sec Filings
- 9/18/24 - Form 3
- 9/17/24 - Form 4
- 9/17/24 - Form 4
- LLY's page on the SEC website